2KRT

Solution NMR Structure of a Conserved Hypothetical Membrane Lipoprotein Obtained from Ureaplasma parvum: Northeast Structural Genomics Consortium Target UuR17A (139-239)

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
2	2D 1H-13C HSQC	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
3	3D 1H-15N/13C simultaneous NOESY	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
4	3D 1H-13C arom NOESY	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
5	2D 1H-15N HSQC	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
6	2D 1H-13C HSQC	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
7	3D CBCA(CO)NH	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
8	3D HBHA(CO)NH	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
9	3D HNCO	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
10	3D HNCA	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
11	3D HNCACB	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
12	(4,3)D GFT-CBCACACONHN	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
13	(4,3)D GFT-HNNCABCA	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
14	3D CCH-TOCSY	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
15	3D HCCH-TOCSY	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
16	3D CCCONH TOCSY	0.91 mM [U-100% 13C; U-100% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
17	3D HNHA	0.7 mM [U-10% 13C; U-99% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298
18	Het NOE	0.7 mM [U-10% 13C; U-99% 15N] UuR17A, Lipoprotein	95% H2O/5% D2O	5mM CaCl2, 10mM Nacl	6.5	ambient	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	800
2	Varian	INOVA	600
3	Varian	INOVA	500

NMR Refinement
Method	Details	Software
simulated annealing	The structure was obtained using triple resonance NMR spectroscopy. GFT_NMR experiments were used for backbone resosnance assignments and conventional 3D TOCSY experiments were used for sidechain assignments. Automated NOESY assignments were made using AUTOSTRUCTURE and CYANA-3.0 software. Dihedral angle constraints were obtained using TALOS. The structure calculation was done excluding the 8-residue C-terminal tag (LEHHHHHH). Final structure quality factor excluding C-terminal tag: as determined by PSVS-v1-4: Ordered residues are defined as 5-71, 74-114. (a) RMSD (ordered residue) all backbone atoms - 0.7A, heacyatoms - 1.1A. (b) Ramachandran statistics for ordered residues: Most favored region: 85.1%, additionally favored: 14.6%, Generously allowed: 0.4%. (c) Procheck scores for ordered residues (RAW/Z): Phi/psi - -0.42/-1.34, all - -0.40/-2.37. (d) MolProbity clashscores (RAW/Z) - 21.86/-2.23. (e) RPF scores for the goodness fit to NOESY data: Recall - 0.917, Precision - 0.928, F-measure 0.923 and final dp-score - 0.755.	CNS

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	150
Conformers Submitted Total Number	20
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	refinement	CNS	2.0.6	Brunger, Adams, Clore, Gros, Nilges and Read
2	structure solution	CYANA	3.0	Guntert, Mumenthaler and Wuthrich
3	structure solution	AutoStructure	2.2.1	Huang, Tejero, Powers and Montelione
4	chemical shift assignment	PINE	1.0	Bahrami, Markley, Assadi, and Eghbalnia
5	chemical shift assignment	AutoAssign	2.2.1	Zimmerman, Moseley, Kulikowski and Montelione

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.